Breast cancer is the most prevalent type of tumor and the second leading cause of death
due to cancer among women. Although screening methods, diagnosis and therapeutic …

Breast cancer (BC) affects over 250,000 women in the US each year. Drug-resistant cancer
cells are responsible for most breast cancer fatalities. Scientists are developing novel …

Drug resistance is a major challenge in breast cancer (BC) treatment at present.
Accumulating studies indicate that breast cancer stem cells (BCSCs) are responsible for the …

The journey of chemotherapeutic drugs from the site of administration to the site of action is
confronted by several factors including low bioavailability, uneven distribution in major …

Simple Summary Triple negative breast cancer lacks targeted therapies and has poor
prognosis; chemotherapy is currently the main treatment modality. Growing evidence has …

Titanium carbide MXene quantum dots (MQDs) possess intrinsic regulatory properties and
selective toxicity to cancer cells. Here, MDQs were selected for the modification of …

Despite the leaps and bounds in achieving success in the management and treatment of
breast cancers through surgery, chemotherapy, and radiotherapy, breast cancer remains the …

Simple Summary Lately, human cytomegalovirus (HCMV) has been progressively
implicated in carcinogenesis alongside its oncomodulatory impact. CMV-Transformed …

Targeted drug delivery by nanocarriers molecules can increase the efficiency of cancer
treatment. One of the targeting ligands is folic acid (FA), which has a high affinity for the folic …

Background Stemness, a key component of breast cancer (BC) heterogeneity, is responsible
for chemoresistance. Growth differentiation factor-15 (GDF-15) induces drug resistance and …